|Biotech Due Diligence||
Click to expand.
Actavis $ACT (renamed from Watson Pharma $WPI after merger) is one of numerous companies pursuing biosimilars, in collaboration with Amgen $AMGN. Here are there recent comments from the 1q-2013 earnings call (c/o SeekingAlpha). Note that their commercialization deal with Antares Pharma $ATRS for GELNIQUE was not discussed.
Antares Pharma $ATRS has a number of product partnerships with Teva Pharmaceuticals $TEVA based around a series of parenteral injection devices. These deals have been shrouded in secrecy and also littered with delays over the years. Recently though Teva briefly addressed the Epi-pen program on their 1q-2013 conference call (excerpt via SeekingAlpha).
Just curious to know your confidence level in the FDA's ability to approve EpiPen, an AB-rated EpiPen in 2015?
So, just to your second on question on EpiPen, I will let you know we had a settlement with Mylan and we have an entry date in 2015. The trial Is progressing well.
This post features comments from the Teva Pharmaceuticals $TEVA year-end 2012 earnings conference call that are relevant to companies covered here at BiotechDueDiligence.
As usual the discussion centers COPAXONE for multiple sclerosis, which Momenta Pharmaceutical $MNTA and partner Sandoz (Novartis $NVS) are seeking approval for a generic version of.
MNTA and biosimilars - notes from other biotech/pharma conference calls
Other blog posts related to TEVA and MNTA
Another set of investor relations (IR) questions and responses from biotechs provided by Mike O'Neill has been posted, covering financials and upcoming catalysts for each biotech stock.
This round of responses features Antares Pharma ATRS, Durata Therapeutics DRTX, AcelRx Pharma ACRX, Acasti Pharma ACST, and IntelGenx Technologies IGXT.
Check out the complete index of all IR Questions and Answers if you missed the previous editions (covering >50 biotech and pharmaceutical companies)